Drug intelligence / Profile preview

lutetium-177 rhPSMA-10.1

Development stage: Unknown
Lead developer: Blue Earth Therapeutics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lutetium-177 rhPSMA-10.1 is a next-generation radiohybrid (rh) PSMA-targeted radioligand therapy being developed by Blue Earth Therapeutics for the treatment of metastatic prostate cancer. The "radiohybrid" technology allows the same molecule to be labeled with either diagnostic (e.g., Fluorine-18) or therapeutic (e.g., Lutetium-177) radioisotopes, facilitating a precise theranostic approach. The drug consists of a small-molecule ligand that binds with high affinity to the Prostate-Specific Membrane Antigen (PSMA) expressed on prostate cancer cells, delivering the beta-emitting radioisotope Lutetium-177 directly to the tumor site to induce DNA damage and cell death. It is currently being evaluated in clinical trials to compare its dosimetry and efficacy against established PSMA-targeted therapies like Pluvicto.

Other names: lutetium Lu 177 rhPSMA-10.1

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on lutetium-177 rhPSMA-10.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium-177 rhPSMA-10.1.

Explore the full profile